These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 12907443)

  • 1. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
    Saunthararajah Y; Hillery CA; Lavelle D; Molokie R; Dorn L; Bressler L; Gavazova S; Chen YH; Hoffman R; DeSimone J
    Blood; 2003 Dec; 102(12):3865-70. PubMed ID: 12907443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
    Saunthararajah Y; DeSimone J
    Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
    Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
    Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA hypo-methylating agents and sickle cell disease.
    Saunthararajah Y; Lavelle D; DeSimone J
    Br J Haematol; 2004 Sep; 126(5):629-36. PubMed ID: 15327513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
    Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
    PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
    DeSimone J; Koshy M; Dorn L; Lavelle D; Bressler L; Molokie R; Talischy N
    Blood; 2002 Jun; 99(11):3905-8. PubMed ID: 12010787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of subcutaneous decitabine in β-thalassemia intermedia.
    Olivieri NF; Saunthararajah Y; Thayalasuthan V; Kwiatkowski J; Ware RE; Kuypers FA; Kim HY; Trachtenberg FL; Vichinsky EP;
    Blood; 2011 Sep; 118(10):2708-11. PubMed ID: 21700776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis).
    Lavelle D; Saunthararajah Y; Vaitkus K; Singh M; Banzon V; Phiasivongsva P; Redkar S; Kanekal S; Bearss D; Shi C; Inloes R; DeSimone J
    J Transl Med; 2010 Oct; 8():92. PubMed ID: 20932295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of fetal hemoglobin-enhancing agents in thalassemia.
    Lal A; Vichinsky E
    Semin Hematol; 2004 Oct; 41(4 Suppl 6):17-22. PubMed ID: 15534853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin.
    Humphries RK; Dover G; Young NS; Moore JG; Charache S; Ley T; Nienhuis AW
    J Clin Invest; 1985 Feb; 75(2):547-57. PubMed ID: 2579100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
    Atweh GF; Schechter AN
    Curr Opin Hematol; 2001 Mar; 8(2):123-30. PubMed ID: 11224687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of fetal hemoglobin in the treatment of sickle cell disease.
    Fathallah H; Atweh GF
    Hematology Am Soc Hematol Educ Program; 2006; ():58-62. PubMed ID: 17124041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
    Fibach E; Prasanna P; Rodgers GP; Samid D
    Blood; 1993 Oct; 82(7):2203-9. PubMed ID: 7691251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis.
    Lavelle D; Chin J; Vaitkus K; Redkar S; Phiasivongsa P; Tang C; Will R; Hankewych M; Roxas B; Singh M; Saunthararajah Y; Desimone J
    Am J Hematol; 2007 Nov; 82(11):981-5. PubMed ID: 17696208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies to increase fetal hemoglobin in sickle cell disease.
    Steinberg MH
    Curr Hematol Rep; 2003 Mar; 2(2):95-101. PubMed ID: 12901139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.
    Dover GJ; Charache SH; Boyer SH; Talbot CC; Smith KD
    Prog Clin Biol Res; 1983; 134():475-88. PubMed ID: 6198661
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Gilmartin AG; Groy A; Gore ER; Atkins C; Long ER; Montoute MN; Wu Z; Halsey W; McNulty DE; Ennulat D; Rueda L; Pappalardi M; Kruger RG; McCabe MT; Raoof A; Butlin R; Stowell A; Cockerill M; Waddell I; Ogilvie D; Luengo J; Jordan A; Benowitz AB
    Haematologica; 2021 Jul; 106(7):1979-1987. PubMed ID: 32586904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiation.
    Ruiz MA; Rivers A; Ibanez V; Vaitkus K; Mahmud N; DeSimone J; Lavelle D
    Epigenetics; 2015; 10(5):397-407. PubMed ID: 25932923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.